[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Consorci Sanitari del Maresme\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":116},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,70,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100587245","effect-of-micronized-creatine-monohydrate-on-muscle-mass-strength-and-performance-in-older-adults-submitted-to-total-knee-arthroplasty-100587245",false,"NCT06925880","Effect of Micronized Creatine Monohydrate on Muscle Mass, Strength and Performance in Older Adults Submitted to Total Knee Arthroplasty","Efficacy of Supplementation With Micronized Creatine Monohydrate in the Recovery of Muscle Mass, Muscle Strength and Functional Capacity in Older Adults Operated on for Total Knee Arthroplasty: Randomized Clinical Trial","CREAR","Inclusion Criteria:\n\n* Persons 65 years of age or older who have been operated on for the first time for total knee arthroplasty,\n* who are undergoing an outpatient rehabilitation program according to standard clinical practice,\n* who sign the informed consent form.\n\nExclusion Criteria:\n\n* Chronic renal disease at stage G3b or higher or glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2.\n* Hepatic insufficiency, cirrhosis.\n* Neuromuscular and neurodegenerative diseases (amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, Parkinson's disease, etc.).\n* Severe or very severe chronic obstructive pulmonary disease (COPD) (GOLD III-IV).\n* Moderate or severe chronic heart failure (NYHA 3-4).\n* Central sensitivity syndrome (fibromyalgia and chronic fatigue syndrome).\n* Moderate or severe cognitive impairment (GDS≥4).\n* Moderate-severe dependence for basic activities of daily living (preintervention Barthel index \\\u003C60 points).\n* Hemiparesis, amputation or malformation of any limb.\n* Consumption of creatine monohydrate supplements in the last 6 months.","ALL","65 Years",{"count":20,"type":21},262,"ESTIMATED","INTERVENTIONAL",[24],"NA","Double-blind randomized placebo-controlled clinical trial with two parallel arms. The main objective is to evaluate the efficacy and safety of creatine supplementation in older adults who have been operated on for total knee arthroplasty and undergoing a usual rehabilitation program. The intervention will consist of daily creatine monohydrate supplementation for 12 weeks. The intervention will start after surgery with a loading dose of 20g\u002Fday for 1 week and then continue with a maintenance dose of 5g\u002Fday for 11 weeks.\n\nMain outcome mesures included muscle mass, muscle strenght, sarcopenia, frailty, functional capacity and physical performance and will be assessed at baseline, 3 and 6 months follow-up.",[27,28,29,30,31,32],"Sarcopenia in Elderly","Frailty at Older Adults","Functional Capacity","Creatine Supplementation","Arthroplasties, Knee Replacement","Physical Performance","RECRUITING","2026-03-25",{"date":36,"type":37},"2026-03-30","ACTUAL",{"date":39,"type":37},"2025-06-10",{"date":41,"type":21},"2027-10-31",{"name":43,"class":44},"Consorci Sanitari del Maresme","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100402342","effectiveness-and-security-testing-of-a-mobile-app-100402342","NCT04519008","Effectiveness and Security Testing of a Mobile App","Effectiveness and Security Testing of a Mobile App (B·RIGHT) for Adolescents With Attention-Deficit\u002FHyperactivity Disorder and Emotion Dysregulation","Inclusion Criteria:\n\n* DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) of attention-deficit\u002Fhyperactivity disorder\n* High emotion dysregulation severity\n* Aged 14 to 17 years\n* Outpatient setting (Consorci Sanitari del Maresme\n\nExclusion Criteria:\n\n* Comorbidity with mental retardation\n* Comorbidity with psychotic disorder\n* Comorbidity with autism spectrum disorder","14 Years","17 Years",{"count":56,"type":21},80,[24],"To assess the effectiveness and security of a mobile App (beta version) for self-managing emotion dysregulation in a pragmatic randomized controlled trial with 80 adolescents with attention-deficit\u002Fhyperactivity disorder comparing 40 patients with treatment as usual (TAU) with 40 patients with TAU plus the mobile App",[60],"Attention Deficit Disorder With Hyperactivity","NOT_YET_RECRUITING","2024-09-12",{"date":64,"type":37},"2024-09-19",{"date":66,"type":21},"2026-10-01",{"date":68,"type":21},"2028-09-15",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":17,"minAge":78,"maxAge":18,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100378676","effectiveness-and-security-testing-of-a-mobile-app-for-self-managing-emotion-dysregulation-100378676","NCT04210648","Effectiveness and Security Testing of a Mobile App for Self-Managing Emotion Dysregulation","Effectiveness and Security Testing of a Mobile App for Self-Managing Emotion Dysregulation in a Non-Clinical Population With Borderline Traits: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Borderline traits\n* Aged between 18 to 65 years\n* College students\n\nExclusion Criteria:\n\n* None",true,"18 Years",{"count":56,"type":21},[24],"To assess the effectiveness and security of a mobile App (beta version) for people with borderline traits recruited from a non-clinical population of college students in Barcelona (Spain). The main primary outcome will be the severity of the emotional dysregulation. Forty participants will use the mobile app over 6 months. This group while be compared at post-treatment and at 3-month follow-up with other 40 participants (control group) with any intervention.",[83],"Emotional Dysregulation",{"date":64,"type":37},{"date":86,"type":21},"2026-09",{"date":88,"type":21},"2028-10",{"name":43,"class":44},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":45},"100378761","effectiveness-and-security-testing-of-a-mobile-app-bright-for-emotional-crisis-in-borderline-personality-disorder-100378761","NCT04211753","Effectiveness and Security Testing of a Mobile App (B·RIGHT) for Emotional Crisis in Borderline Personality Disorder","Effectiveness and Security Testing of a Mobile App (B·RIGHT) for Self-managing Emotional Crises in People With Borderline Personality Disorder: A Pragmatic Randomized Controlled Trial","B·RIGHT","Inclusion Criteria:\n\n* DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) of borderline personalidad disorder (BPD)\n* Aged 18-60 yeats old\n\nExclusion Criteria:\n\n* Comorbidity with mental retardation\n* Comorbidity with psychotic disorder\n* Comorbidity with antisocial personality\n* Comorbidity with autism spectrum disorder","60 Years",{"count":56,"type":21},[24],"To assess the effectiveness and security of a mobile App (beta version) for self-managing emotional crisis in a pragmatic randomized controlled trial with 80 patients with borderline personality disorder (40 patients with treatment as usual, TAU) versus 40 patients with TAU plus the mobile App)",[103],"Borderline Personality Disorder",[105,106,107,108,109],"Borderline personality disorder","Mobile app","Crisis intervention","Effectiveness","Security",{"date":64,"type":37},{"date":112,"type":21},"2025-02",{"date":114,"type":21},"2025-06",{"name":43,"class":44},""]